TP53 and melanoma: In the light of the findings that malignant melanoma belongs to tumors retaining wild-type p53 but its function is limited by the overproduction of its negative regulators Mdm2 and MdmX, we searched for compounds that could restore p53 activity by targeting Mdm2 and MdmX.